[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-1-research--":3,"news-meta":441},{"data":4,"pagination":437},[5,61,107,152,204,255,302,352,395],{"_id":6,"slug":7,"articleType":8,"body":9,"createdAt":16,"dek":17,"entities":18,"headline":33,"imageAlt":34,"imageUrl":35,"keyFacts":36,"language":50,"publishedAt":51,"seo":52,"sources":55,"summary":59,"updatedAt":60},"6a9969705457399f4e5dcefc","medical-cannabis-shows-promise-in-dentistry-for-pain-and-inflammation-review-finds-b43ddd1c","research",[10,11,12,13,14,15],"Medical cannabis has promising therapeutic potential in dentistry, according to a new scientific review published in Fitos Journal. The paper, authored by researchers from the Health Department of the Federal District, School of Public Health of the Federal District, and Higher Education Institute of Brasília, analyzed 59 previously published studies and found theoretical and scientific support for using medicinal cannabis in dental care.","The review highlights that endocannabinoid receptors are present throughout the oral cavity, including the oral mucosa, dental pulp, periodontal tissues, salivary glands, and temporomandibular joints. Activating these receptors could provide targeted pain relief, reduce inflammation, and offer antimicrobial effects, the authors said.","One study included in the review concluded that cannabinoids have a therapeutic effect in reducing pain perception, especially for trigeminal neuralgia, persistent idiopathic facial pain, burning mouth syndrome, and post-herpetic neuralgia. The authors noted that orofacial pain is among the most common conditions in dental care, and cannabis appears to be an important ally in treating these discomforts, potentially enhancing or even replacing existing medications.","The paper also identified potential applications in periodontics, bruxism, and management of oral mucositis. However, the researchers cautioned that while current evidence is promising and cannabis is considered a safe therapy, randomized controlled trials are needed to more robustly confirm its efficacy and safety.","The authors also pointed to regulatory challenges, noting a lack of adequate regulation in Brazil and elsewhere that can lead to inequalities in access, favoring those who can afford expensive products. They also highlighted the lack of standardization in dosing due to individual variability in the endocannabinoid system.","This review adds to prior research on cannabis and oral health, including studies on CBD mouthwash for oral microbiome homeostasis and a 2023 paper finding that a single dose of CBD is as potent as current analgesic regimens for emergency dental pain.","2026-09-03T12:34:56.710Z","A new scientific review suggests cannabinoids could improve patient quality of life during dental treatments by managing orofacial pain, periodontal disease, and other oral conditions.",{"brands":19,"products":20,"markets":24,"organizations":27},[],[21,22,23],"medical cannabis","cannabidiol (CBD)","cannabigerol (CBG)",[25,26],"Brazil","US",[28,29,30,31,32],"Health Department of the Federal District","School of Public Health of the Federal District","Higher Education Institute of Brasília","Fitos Journal","Marijuana Moment","Medical Cannabis Shows Promise in Dentistry for Pain and Inflammation, Review Finds","Dental tools and a cannabis leaf on a table, representing the integration of medical cannabis into dentistry.","",[37,41,44,47],{"claim":38,"sourceUrl":39,"_id":40},"A scientific review of 59 studies found theoretical and scientific support for the potential therapeutic uses of medicinal cannabis in dentistry.","https:\u002F\u002Fwww.marijuanamoment.net\u002Fintegrating-medical-cannabis-into-dentistry-can-boost-patient-quality-of-life-during-treatments-study-finds\u002F","6a996970723e26a876d6777c",{"claim":42,"sourceUrl":39,"_id":43},"Cannabinoids may reduce pain perception in conditions such as trigeminal neuralgia, persistent idiopathic facial pain, burning mouth syndrome, and post-herpetic neuralgia.","6a996970723e26a876d6777d",{"claim":45,"sourceUrl":39,"_id":46},"Endocannabinoid receptors are identified throughout the oral cavity, including oral mucosa, dental pulp, periodontal tissues, salivary glands, and temporomandibular joints.","6a996970723e26a876d6777e",{"claim":48,"sourceUrl":39,"_id":49},"The review calls for randomized controlled trials to confirm efficacy and safety, and highlights regulatory and cost barriers to equitable access.","6a996970723e26a876d6777f","en","2026-09-03T12:34:58.157Z",{"title":53,"description":54},"Medical Cannabis in Dentistry: Review Finds Promise","A new review suggests medical cannabis may help manage dental pain and inflammation, but more research and regulation are needed.",[56],{"name":32,"url":39,"trustTier":57,"_id":58},"trade","6a996970723e26a876d6777b","A review of 59 studies by Brazilian researchers indicates that medical cannabis has therapeutic potential in dentistry, particularly for orofacial pain, refractory periodontal diseases, and burning mouth syndrome. The authors call for more clinical trials and better regulation to ensure equitable access.","2026-09-03T12:34:58.158Z",{"_id":62,"slug":63,"articleType":8,"body":64,"createdAt":71,"dek":72,"entities":73,"headline":81,"imageAlt":82,"imageUrl":35,"keyFacts":83,"language":50,"publishedAt":97,"seo":98,"sources":101,"summary":105,"updatedAt":106},"6a992be15457399f4e5dcef6","sexually-suggestive-cannabis-ads-may-shape-young-adults-intentions-to-use-before-sex-study-finds-31e39825",[65,66,67,68,69,70],"A new study from Washington State University indicates that cannabis marketing messages about better sex may influence young adults' plans to consume cannabis before sexual activity. The research, published in the journal Communication Research, found that college students who interpreted ads as suggesting cannabis use resulted in better sex were more likely to expect those benefits and to say they might use cannabis before sex.","The study included 747 Washington college students who were shown specific ads that had appeared on Instagram. Researchers examined how different people interpreted the same messages and whether those interpretations were connected to their expectations and intentions.","Simply viewing a sexual or romantic ad did not consistently predict viewers' answers. What mattered more was how they interpreted it. Those who believed an ad was promising better sex were more likely to expect cannabis to improve their own sexual experiences or reduce nervousness, and they were more likely to say they might use cannabis before sex.","Jessica Fitts Willoughby, a professor in WSU's Edward R. Murrow College of Communication and the study's lead author, noted that researchers know from alcohol advertising that sexualized appeals can make a difference in how people understand the information presented. She added that cannabis is a little different because there really aren't rules saying you can't tie it to sex.","The study also found differences between men and women. Men who wanted to be like the men shown in sexual or romantic ads were more likely to say they intended to use cannabis before sex. Women who thought the ads raised concerns about sexual consent were less likely to say they would use cannabis before sex.","Stacey J.T. Hust, a professor in the Murrow College and co-author of the study, said the findings suggest that those messages could make people, particularly women, less likely to intend to use cannabis before sex. The study was published online on August 31.","2026-09-03T08:12:17.424Z","Washington State University researchers found that how college students interpret cannabis marketing messages matters more than the ad's sexual imagery itself.",{"brands":74,"products":75,"markets":76,"organizations":78},[],[],[77,26],"Washington",[79,80],"Washington State University","Edward R. Murrow College of Communication","Sexually Suggestive Cannabis Ads May Shape Young Adults' Intentions to Use Before Sex, Study Finds","Researchers examine how young adults interpret sexually suggestive cannabis advertisements on social media and whether those interpretations influence intentions to use cannabis before sex.",[84,88,91,94],{"claim":85,"sourceUrl":86,"_id":87},"A Washington State University study found that college students who interpreted cannabis ads as suggesting better sex were more likely to expect those benefits and to say they might use cannabis before sex.","https:\u002F\u002Fganjapreneur.com\u002Fstudy-sexually-suggestive-cannabis-ads-may-influence-young-adults-decision-to-use-cannabis-before-sex\u002F","6a992be1723e26a876d639e9",{"claim":89,"sourceUrl":86,"_id":90},"The research included 747 Washington college students who were shown specific ads that had appeared on Instagram.","6a992be1723e26a876d639ea",{"claim":92,"sourceUrl":86,"_id":93},"Men who wanted to be like the men shown in sexual or romantic ads were more likely to say they intended to use cannabis before sex, while women who thought the ads raised concerns about sexual consent were less likely to say they would use cannabis before sex.","6a992be1723e26a876d639eb",{"claim":95,"sourceUrl":86,"_id":96},"The study was published online on August 31 in the journal Communication Research.","6a992be1723e26a876d639ec","2026-09-03T08:12:19.258Z",{"title":99,"description":100},"Cannabis Ads May Shape Young Adults' Use Before Sex","Washington State University study finds interpretation of sexually suggestive cannabis ads may influence young adults' intentions to use cannabis before sex.",[102],{"name":103,"url":86,"trustTier":57,"_id":104},"Ganjapreneur","6a992be1723e26a876d639e8","A new study from Washington State University suggests that cannabis ads interpreted as promising better sex may influence young adults' expectations and intentions to use cannabis before sexual activity. The research, involving 747 Washington college students, found that personal interpretation of ad messages was a stronger predictor of intended use than simply viewing sexual or romantic imagery.","2026-09-03T08:12:19.261Z",{"_id":108,"slug":109,"articleType":8,"body":110,"createdAt":116,"dek":117,"entities":118,"headline":127,"imageAlt":128,"imageUrl":35,"keyFacts":129,"language":50,"publishedAt":143,"seo":144,"sources":147,"summary":150,"updatedAt":151},"6a9872655457399f4e5dceea","newly-released-va-records-raise-questions-about-how-cannabis-use-disorder-diagnoses-are-affecting-veterans-1d4f5e14",[111,112,113,114,115],"Newly released Department of Veterans Affairs records obtained through a Freedom of Information Act request by the Veterans Action Council are raising questions about how cannabis use disorder diagnoses are being applied to veterans within the Veterans Health Administration. The documents, detailed in an op-ed by Etienne Fontan of the Veterans Action Council, suggest that some veterans may be receiving cannabis use disorder diagnoses without the comprehensive clinical evaluation required by the Diagnostic and Statistical Manual of Mental Disorders.","The 2013 release of the DSM-5 introduced cannabis use disorder as a new diagnosis, replacing the DSM-4 categories of Cannabis Abuse and Cannabis Dependence with a single, severity-based unified diagnosis. According to the op-ed, this consolidation widened the diagnostic net, capturing a broader range of individuals under a single label and creating circumstances in which individuals who previously would not have received a diagnosis could now be classified as having a disorder.","Internal VA records obtained through the FOIA request show that in 2022, VA correspondence reported 134,790 veterans with cannabis-positive urine drug screens and 139,336 veterans identified as having cannabis use disorder. Research cited within the same FOIA records from the National Epidemiologic Survey on Alcohol and Related Conditions found that 7.3 percent of U.S. veterans reported cannabis use in the previous year, but only 1.8 percent met DSM criteria for cannabis use disorder.","The FOIA records also reveal that VA officials recognized the complexity of the issue. In one email, VA Office of Research and Development Media Branch Chief Bruce I. Friedland acknowledged the need to thread a needle between addressing genuine cannabis-related substance use disorders and supporting research into cannabis as a potential therapeutic treatment. Additional correspondence from UCSF physician Dr. Salomeh Keyhani recommended that veterans identified through urine drug screening be individually assessed for high-risk cannabis use and offered treatment when appropriate.","VA research contained in the FOIA materials also found that nearly one third of reviewed patient records contained no documented discussion of cannabis between providers and patients. Of those that did, nearly half involved medical cannabis use rather than discussions of risks or harm reduction. These findings reinforce the importance of patient-provider dialogue and individualized clinical judgment before assigning a psychiatric diagnosis, according to the op-ed.","2026-09-02T19:00:53.365Z","FOIA records obtained by the Veterans Action Council show a gap between diagnostic standards and real-world application of cannabis use disorder within the Veterans Health Administration.",{"brands":119,"products":120,"markets":121,"organizations":122},[],[],[26],[123,124,125,126],"Veterans Health Administration","Veterans Action Council","American Psychiatric Association","U.S. Department of Veterans Affairs","Newly Released VA Records Raise Questions About How Cannabis Use Disorder Diagnoses Are Affecting Veterans","Veterans Affairs medical records and diagnostic documents related to cannabis use disorder diagnoses for veterans",[130,134,137,140],{"claim":131,"sourceUrl":132,"_id":133},"In 2022, VA correspondence reported 134,790 veterans with cannabis-positive urine drug screens and 139,336 veterans identified as having cannabis use disorder.","https:\u002F\u002Fwww.marijuanamoment.net\u002Fnewly-released-va-records-raise-questions-about-how-cannabis-use-disorder-diagnoses-are-affecting-veterans-op-ed\u002F","6a987265723e26a876d5dc58",{"claim":135,"sourceUrl":132,"_id":136},"Research cited within the FOIA records from the National Epidemiologic Survey on Alcohol and Related Conditions found that 7.3 percent of U.S. veterans reported cannabis use in the previous year, but only 1.8 percent met DSM criteria for cannabis use disorder.","6a987265723e26a876d5dc59",{"claim":138,"sourceUrl":132,"_id":139},"VA research contained in the FOIA materials found that nearly one third of reviewed patient records contained no documented discussion of cannabis between providers and patients.","6a987265723e26a876d5dc5a",{"claim":141,"sourceUrl":132,"_id":142},"The DSM-5 introduced cannabis use disorder as a new diagnosis in 2013, replacing the DSM-4 categories of Cannabis Abuse and Cannabis Dependence with a single, severity-based unified diagnosis.","6a987265723e26a876d5dc5b","2026-09-02T19:00:54.995Z",{"title":145,"description":146},"VA Records Raise Questions on Cannabis Use Disorder Diagnoses","Newly released VA records show 139,336 veterans identified with cannabis use disorder in 2022, while national data found only 1.8 percent of users met criteria.",[148],{"name":32,"url":132,"trustTier":57,"_id":149},"6a987265723e26a876d5dc57","Newly released Department of Veterans Affairs records obtained through a Freedom of Information Act request are raising questions about how cannabis use disorder diagnoses are applied to veterans. The documents show that in 2022, the VA reported 139,336 veterans identified as having cannabis use disorder, while national survey data cited in the same records found only 1.8 percent of veterans who used cannabis met diagnostic criteria. Veterans advocates argue that diagnoses are sometimes entered into medical records without comprehensive clinical evaluation or meaningful consideration of medically authorized cannabis use.","2026-09-02T19:00:54.997Z",{"_id":153,"slug":154,"articleType":8,"body":155,"createdAt":162,"dek":163,"entities":164,"headline":176,"imageAlt":177,"imageUrl":35,"keyFacts":178,"language":50,"publishedAt":195,"seo":196,"sources":199,"summary":202,"updatedAt":203},"6a9829c65457399f4e5dcede","cannabis-shows-therapeutic-promise-for-restless-leg-syndrome-scientific-review-finds-82bb4a6a",[156,157,158,159,160,161],"Cannabis and its components appear to play a role in alleviating the symptoms of restless leg syndrome (RLS), according to a new scientific review published in the Annals of Indian Academy of Neurology. RLS is a neurological disorder characterized by an urge to move the legs, sometimes accompanied by sensations like tingling or aching.","Researchers at the All India Institute of Medical Sciences conducted a comprehensive search of previously published studies and included seven papers in their review. They concluded that current evidence indicates cannabis, in various forms, may alleviate or prevent RLS symptoms through multiple mechanisms, though they cautioned that studies to date are limited to case reports, cross-sectional surveys, and post hoc analyses.","The review highlights several existing studies providing initial evidence for cannabinoids' efficacy. In one study, every patient saw complete relief in their symptoms after starting cannabis. Another found that all patients except one reported complete or near-complete improvement in RLS symptoms with marijuana smoking. A third study found that half of patients with end-stage renal disease reported complete relief from RLS symptoms after using cannabis.","The authors noted that topical application of CBD improved RLS significantly after two weeks, and smoked marijuana provided better relief compared to medical cannabis. They concluded that use of illicit or medical cannabis can either prevent or improve symptoms of RLS, including refractory RLS, but reiterated that the existing evidence base is of low quality due to the lack of randomized controlled trials.","Despite these limitations, the researchers said existing evidence indicates a potential role for cannabis in managing RLS, primarily when available therapies do not provide optimal relief, lose efficacy over time, or have disabling adverse effects. They added that the results invite cautious optimism regarding the role of cannabis and cannabinoids in RLS, positioning cannabis as a potential adjunct rather than a replacement for established therapies.","A separate recently published study found that people with RLS could experience significant long-term relief with cannabis treatment. That research showed a cannabis product containing 2.7mg THC and 2.5mg CBD was effective in reducing RLS severity among patients with multiple sclerosis and associated idiopathic RLS, with improvements observed after one and three months and maintained after one year among patients who continued therapy.","2026-09-02T13:51:02.980Z","A new scoping review from Indian researchers concludes that cannabis and CBD may improve or prevent symptoms of restless leg syndrome, though high-quality trials are still needed.",{"brands":165,"products":166,"markets":171,"organizations":173},[],[167,168,169,21,170],"CBD","THC","cannabidiol","marijuana",[172],"India",[174,175],"All India Institute of Medical Sciences","Annals of Indian Academy of Neurology","Cannabis Shows 'Therapeutic Promise' for Restless Leg Syndrome, Scientific Review Finds","Scientific review suggests cannabis and CBD may hold therapeutic promise for restless leg syndrome symptoms.",[179,183,186,189,192],{"claim":180,"sourceUrl":181,"_id":182},"Cannabinoids—particularly CBD—may hold therapeutic promise in RLS through multi-system neurobiological effects, according to a study published in the Annals of Indian Academy of Neurology.","https:\u002F\u002Fwww.marijuanamoment.net\u002Fcannabis-has-therapeutic-promise-for-people-with-restless-leg-syndrome-scientific-review-concludes\u002F","6a9829c6723e26a876d5bc63",{"claim":184,"sourceUrl":181,"_id":185},"Researchers at the All India Institute of Medical Sciences conducted a comprehensive search of previously published studies and included seven papers in their review.","6a9829c6723e26a876d5bc64",{"claim":187,"sourceUrl":181,"_id":188},"Every patient in one study saw complete relief in their symptoms after starting cannabis, and another study found all patients except one reported complete or near-complete improvement in RLS symptoms with marijuana smoking.","6a9829c6723e26a876d5bc65",{"claim":190,"sourceUrl":181,"_id":191},"The review authors concluded that use of illicit or medical cannabis can either prevent or improve symptoms of RLS, including refractory RLS, but noted the existing evidence base is of low quality due to the lack of randomized controlled trials.","6a9829c6723e26a876d5bc66",{"claim":193,"sourceUrl":181,"_id":194},"A separate study found that a cannabis product containing 2.7mg THC and 2.5mg CBD was effective in reducing RLS severity among patients with multiple sclerosis and associated idiopathic RLS, with improvements maintained after one year among patients who continued therapy.","6a9829c6723e26a876d5bc67","2026-09-02T13:51:05.634Z",{"title":197,"description":198},"Cannabis Shows Promise for Restless Leg Syndrome","A scientific review finds cannabis and CBD may improve or prevent restless leg syndrome symptoms, though high-quality trials are still needed.",[200],{"name":32,"url":181,"trustTier":57,"_id":201},"6a9829c6723e26a876d5bc62","A scientific review published in the Annals of Indian Academy of Neurology finds that cannabis and its components, particularly CBD, may hold therapeutic promise for restless leg syndrome (RLS). Researchers from the All India Institute of Medical Sciences analyzed seven existing studies and concluded that cannabis could alleviate or prevent RLS symptoms, but cautioned that current evidence is limited to case reports and surveys.","2026-09-02T13:51:05.639Z",{"_id":205,"slug":206,"articleType":8,"body":207,"createdAt":215,"dek":216,"entities":217,"headline":228,"imageAlt":229,"imageUrl":35,"keyFacts":230,"language":50,"publishedAt":246,"seo":247,"sources":250,"summary":253,"updatedAt":254},"6a96c5cb5457399f4e5dcec8","high-dose-thc-can-produce-psychedelic-like-states-johns-hopkins-study-finds-153b0440",[208,209,210,211,212,213,214],"High doses of THC from cannabis may produce psychoactive effects that are difficult to distinguish from those caused by the psychedelic psilocybin, according to a new study from the Johns Hopkins University School of Medicine.","The pilot investigation involved four adults who underwent three or four sessions during which they received either 25 milligrams of psilocybin, 25 milligrams of THC, 50 milligrams of THC, or a placebo. The THC was administered either as synthetic dronabinol or as a whole-plant cannabis distillate extract.","Both participants and session facilitators were blinded to what was actually received at the time and were asked to guess afterwards. Every participant correctly identified when they had received a placebo or the real psychedelic, but the 25 mg dronabinol condition was rated as more similar to a classic psychedelic or dissociative than a cannabinoid.","The whole-plant cannabis distillate extract of THC was rated by participants as having a stronger overall subjective drug effect than equivalent doses of synthetic dronabinol. The paper, published in the journal Psychopharmacology, stated that 25 mg of THC in both forms yielded a subjective experience similar to 25 mg psilocybin.","Researchers said the results could have implications for future clinical trials of psychedelics by helping to address the problem of unblinding, where participants are able to tell whether they have received the drug being tested, a placebo, or a comparator substance. An appropriate dose of THC may provide an adequate active comparator condition for ongoing psychedelic clinical trials, they suggested.","The study was designed to mimic the set and setting in which psychedelic research is typically carried out. Participants laid on a couch, wore eye shades, listened to music, and were told to turn inward and be present for whatever arises within consciousness.","The study was funded by the Wana Brand Foundation, which was launched by the CEO of the cannabis company Wana Brands.","2026-09-01T12:32:11.026Z","A pilot study suggests oral THC may be mistaken for psilocybin under clinical trial conditions, offering a potential active comparator for psychedelic research.",{"brands":218,"products":220,"markets":224,"organizations":225},[219],"Wana Brands",[168,221,222,223],"dronabinol","cannabis distillate extract","psilocybin",[],[226,227],"Johns Hopkins University School of Medicine","Wana Brand Foundation","High-Dose THC Can Produce Psychedelic-Like States, Johns Hopkins Study Finds","Laboratory research setting with cannabis and psychedelic study materials, representing a clinical trial on high-dose THC and psilocybin effects.",[231,235,238,241,244],{"claim":232,"sourceUrl":233,"_id":234},"High doses of THC from marijuana may have psychoactive effects that are hard to distinguish from those caused by the psychedelic psilocybin, according to a new study.","https:\u002F\u002Fwww.marijuanamoment.net\u002Fhigh-doses-of-thc-from-cannabis-can-produce-psychedelic-like-states-study-shows\u002F","6a96c5cb723e26a876d52898",{"claim":236,"sourceUrl":233,"_id":237},"The study was conducted by researchers with the Johns Hopkins University School of Medicine and involved four adults who underwent three or four sessions.","6a96c5cb723e26a876d52899",{"claim":239,"sourceUrl":233,"_id":240},"The 25 mg dronabinol condition was rated as more similar to a classic psychedelic or dissociative than a cannabinoid.","6a96c5cb723e26a876d5289a",{"claim":242,"sourceUrl":233,"_id":243},"25 mg of THC in both forms yielded a subjective experience similar to 25 mg psilocybin.","6a96c5cb723e26a876d5289b",{"claim":214,"sourceUrl":233,"_id":245},"6a96c5cb723e26a876d5289c","2026-09-01T12:32:12.626Z",{"title":248,"description":249},"High-Dose THC Can Produce Psychedelic-Like States, Study Shows","A Johns Hopkins pilot study found oral THC can produce subjective effects similar to psilocybin, potentially serving as an active comparator in psychedelic trials.",[251],{"name":32,"url":233,"trustTier":57,"_id":252},"6a96c5cb723e26a876d52897","Researchers at Johns Hopkins University School of Medicine found that high oral doses of THC can produce subjective effects similar to psilocybin, with some participants unable to distinguish between the two substances. The findings could help address unblinding in psychedelic clinical trials by using THC as an active control.","2026-09-01T12:32:12.629Z",{"_id":256,"slug":257,"articleType":8,"body":258,"createdAt":264,"dek":265,"entities":266,"headline":277,"imageAlt":278,"imageUrl":35,"keyFacts":279,"language":50,"publishedAt":293,"seo":294,"sources":297,"summary":300,"updatedAt":301},"6a95b673aeddfad21a39fa41","federally-funded-study-finds-cancer-patients-need-insurance-coverage-for-medical-marijuana-f0a69398",[259,260,261,262,263],"A new federally funded study of cancer patients who use medical marijuana found that cannabis provided therapeutic benefits for pain, sleep, emotional regulation, and medication reduction, leading researchers to call for insurance coverage of medicinal cannabis.","The paper, published in the journal Frontiers in Psychiatry, surveyed 65 cancer patients and compared those who used CBD-dominant products only with those who used products containing both THC and CBD. Pain relief was the most frequently discussed benefit among all patients, but it was most prominent among those who used THC and CBD products, while emotional regulation was more prominent among CBD-only users.","Researchers from the University of Wisconsin, University of Pennsylvania, Johns Hopkins University, and Realm of Caring Foundation also examined how perceived benefits were interconnected. In the CBD-only group, pain relief was most strongly connected to emotional regulation, medication reduction, sleep or physical relaxation, and appetite stimulation. In the THC and CBD group, pain relief was most often connected to sleep or physical relaxation, emotional regulation, medication reduction, and appetite stimulation.","The study, funded by the National Cancer Institute, the National Institute on Drug Abuse, and the Realm of Caring Foundation, also asked patients about barriers to access. The most frequently reported barriers were stigma associated with THC use and the high cost of CBD-dominant and THC-dominant products.","The authors wrote that the findings highlight \"the need for insurance coverage of medicinal cannabis to reduce the financial burden for this patient population.\" They noted limitations including self-selection and self-report bias, and called for future research with larger, more diverse samples and objective measures of cannabinoid efficacy.","2026-08-31T17:14:27.537Z","Researchers report that cannabis relieves pain, improves sleep, and reduces medication use, but stigma and high costs block access.",{"brands":267,"products":268,"markets":269,"organizations":270},[],[],[26],[271,272,273,274,275,276],"University of Wisconsin","University of Pennsylvania","Johns Hopkins University","Realm of Caring Foundation","National Cancer Institute","National Institute on Drug Abuse","Federally Funded Study Finds Cancer Patients Need Insurance Coverage for Medical Marijuana","Cancer patient holding a bottle of medical cannabis oil, with a researcher reviewing study data in the background.",[280,284,287,290],{"claim":281,"sourceUrl":282,"_id":283},"A federally funded study found that cannabis use conferred therapeutic benefits for cancer patients, including pain relief, improved sleep, physical relaxation, emotional regulation, and reduction of concomitant medication.","https:\u002F\u002Fwww.marijuanamoment.net\u002Ffederally-funded-cancer-study-highlights-need-to-cover-medical-marijuana-under-insurance-researchers-say\u002F","6a95b6730385656fb2e48a0c",{"claim":285,"sourceUrl":282,"_id":286},"Researchers said the results underscore the need for insurance coverage of medicinal cannabis to reduce the financial burden for cancer patients.","6a95b6730385656fb2e48a0d",{"claim":288,"sourceUrl":282,"_id":289},"The most frequently reported barriers to cannabis use were stigma associated with THC use and the high cost of CBD-dominant and THC-dominant products.","6a95b6730385656fb2e48a0e",{"claim":291,"sourceUrl":282,"_id":292},"The study was funded by the National Cancer Institute, the National Institute on Drug Abuse, and the Realm of Caring Foundation.","6a95b6730385656fb2e48a0f","2026-08-31T17:14:28.958Z",{"title":295,"description":296},"Cancer Study Urges Insurance Coverage for Medical Marijuana","Federally funded research finds cannabis relieves cancer symptoms but stigma and high costs block access, prompting calls for insurance coverage.",[298],{"name":32,"url":282,"trustTier":57,"_id":299},"6a95b6730385656fb2e48a0b","A federally funded study published in Frontiers in Psychiatry found that cancer patients using medical marijuana experienced pain relief, better sleep, emotional regulation, and reduced use of other medications. Researchers said the results highlight the need for insurance coverage of medicinal cannabis to reduce financial burdens and stigma.","2026-08-31T17:14:28.960Z",{"_id":303,"slug":304,"articleType":8,"body":305,"createdAt":313,"dek":314,"entities":315,"headline":325,"imageAlt":326,"imageUrl":35,"keyFacts":327,"language":50,"publishedAt":343,"seo":344,"sources":347,"summary":350,"updatedAt":351},"6a91a75eaeddfad21a39f9fb","medical-cannabis-reduces-pain-insomnia-or-mood-issues-in-91-of-older-adults-study-finds-ce8b74cd",[306,307,308,309,310,311,312],"Medical cannabis was associated with symptom improvement in 91 percent of older adults, according to a preprint study involving 124 people over age 65 who received treatment from a specialized practice in Colombia. Most participants had not previously used marijuana, and the most frequent diagnoses were pain-related and musculoskeletal disorders, cancer, and neurodegenerative or non-degenerative neurological disorders.","Treating physicians recorded symptoms on a four-point scale, and researchers defined improvement as a reduction of at least one point in severity relative to baseline. The paper reported that symptom severity decreased significantly across the three main symptom domains, with improvement in approximately 90 percent of patients.","The first documented improvement occurred at the second visit in 67.7 percent of patients with pain, 65.4 percent of those with insomnia, and 73.9 percent of those with mood or behavioral symptoms. Median times to first improvement were three months for pain, two months for insomnia, and one month for mood or behavioral symptoms.","Median severity scores for pain, insomnia, and mood or behavioral symptoms decreased significantly from baseline to the last available assessment, and no patient showed worsening of symptom severity. The researchers also noted strong effect sizes for descriptive improvements in digestive and motor symptoms, appetite, well-being, and physical strength, though those were not statistically significant.","The study found that clinically effective doses were low, typically using just a few milligrams per day of THC, CBD, or CBG, most commonly administered in oral oil-based formulations. While the overall medication burden remained stable, dose reductions or discontinuations of concomitant medications occurred in a quarter of patients.","The researchers concluded that older adults receiving supervised medical cannabis experienced favorable symptom evolution during follow-up, with a clinically acceptable safety profile and consistently low documented clinically effective doses. They cautioned that the observational nature of the study means causality cannot be inferred, and they plan to follow up with larger cohorts in Colombia, Argentina, and Chile.","The study received funding from the European Union and has been made available as a preprint but has not yet been published in a journal.","2026-08-28T15:21:02.128Z","A preprint study of 124 patients over 65 in Colombia found that supervised medical cannabis was linked to significant symptom improvement, with low clinically effective doses.",{"brands":316,"products":317,"markets":318,"organizations":322},[],[21],[319,320,321],"Colombia","Argentina","Chile",[323,324],"European Union","American Medical Association","Medical Cannabis Reduces Pain, Insomnia Or Mood Issues In 91% Of Older Adults, Study Finds","Older adult receiving supervised medical cannabis treatment in a clinical setting",[328,332,335,338,341],{"claim":329,"sourceUrl":330,"_id":331},"Medical cannabis was associated with symptom improvement in 91 percent of older adults in a preprint study of 124 people over age 65 in Colombia.","https:\u002F\u002Fwww.marijuanamoment.net\u002Fmedical-cannabis-reduces-pain-insomnia-or-mood-issues-in-91-of-older-adults-study-finds\u002F","6a91a75e0385656fb2e2b523",{"claim":333,"sourceUrl":330,"_id":334},"Symptom severity decreased significantly across pain, insomnia, and mood or behavioral symptom domains, with improvement in approximately 90 percent of patients.","6a91a75e0385656fb2e2b524",{"claim":336,"sourceUrl":330,"_id":337},"Clinically effective doses were low, typically using just a few milligrams per day of THC, CBD, or CBG, most commonly in oral oil-based formulations.","6a91a75e0385656fb2e2b525",{"claim":339,"sourceUrl":330,"_id":340},"Dose reductions or discontinuations of concomitant medications occurred in a quarter of patients after starting cannabis.","6a91a75e0385656fb2e2b526",{"claim":312,"sourceUrl":330,"_id":342},"6a91a75e0385656fb2e2b527","2026-08-28T15:21:04.301Z",{"title":345,"description":346},"Medical Cannabis Helps 91% of Older Adults, Study Finds","A preprint study of 124 patients over 65 in Colombia found supervised medical cannabis was linked to significant improvement in pain, insomnia, and mood symptoms.",[348],{"name":32,"url":330,"trustTier":57,"_id":349},"6a91a75e0385656fb2e2b522","A new preprint study reports that 91 percent of older adults receiving supervised medical cannabis experienced at least a one-point reduction in pain, insomnia, or mood and behavioral symptoms. The research followed 124 people over age 65 in Colombia, most of whom had not previously used marijuana, and found progressive symptom improvement across follow-up visits.","2026-08-28T15:21:04.305Z",{"_id":353,"slug":354,"articleType":8,"body":355,"createdAt":361,"dek":362,"entities":363,"headline":370,"imageAlt":371,"imageUrl":35,"keyFacts":372,"language":50,"publishedAt":386,"seo":387,"sources":390,"summary":393,"updatedAt":394},"6a9098b7aeddfad21a39f9d9","gallup-17-of-americans-smoke-cannabis-15-consume-edibles-8ba8291a",[356,357,358,359,360],"Seventeen percent of Americans said they smoke cannabis, according to a Gallup poll released Monday, tying the previous record high found by the pollster in 2023. The smoking rate had dipped to 13% in 2024 before rising to 14% in 2025.","Another 15% of those polled indicated they consume cannabis edibles. The edible figure includes 17% of women and 12% of men, while 15% of women and 18% of men said they smoked cannabis.","The majority of respondents who either smoked or consumed edibles were 30 to 49 years old, at 25% and 20% respectively. Among 18- to 29-year-olds, 23% said they smoked cannabis and 19% said they ate edibles. For adults 50 to 64, 10% reported smoking and 12% reported edible consumption, while the lowest rates were among those 65 and older at 5% and 7%.","Cannabis consumption was more popular among non-college graduates than college graduates. Twenty percent of the non-college graduate cohort said they smoke cannabis and 17% consume edibles, compared to 11% and 12% respectively among college graduates.","The poll found Americans about evenly split on the effect of cannabis on most consumers, with 47% saying it has a very or somewhat positive effect and 46% saying it has a very or somewhat negative effect. U.S. adults were also split in the two previous polls, with a slight positive lean of 53% in 2022 and a slight negative lean of 51% in 2024.","2026-08-27T20:06:15.180Z","Smoking ties the pollster's record high while edibles show a gender gap, with women outpacing men.",{"brands":364,"products":365,"markets":366,"organizations":368},[],[],[367],"United States",[369],"Gallup","Gallup: 17% of Americans Smoke Cannabis, 15% Consume Edibles","Bar chart showing Gallup poll results: 17% of Americans smoke cannabis and 15% consume edibles, with age and gender breakdowns.",[373,377,380,383],{"claim":374,"sourceUrl":375,"_id":376},"17% of Americans said they smoke cannabis, tying the previous record high found by Gallup in 2023.","https:\u002F\u002Fganjapreneur.com\u002Fgallup-17-of-americans-smoke-cannabis-15-consume-edibles\u002F","6a9098b7e81f0249cd72d6a3",{"claim":378,"sourceUrl":375,"_id":379},"15% of Americans indicated they consume cannabis edibles, including 17% of women and 12% of men.","6a9098b7e81f0249cd72d6a4",{"claim":381,"sourceUrl":375,"_id":382},"The majority of respondents who smoked or consumed edibles were 30 to 49 years old, at 25% and 20% respectively.","6a9098b7e81f0249cd72d6a5",{"claim":384,"sourceUrl":375,"_id":385},"47% of Americans say cannabis has a very or somewhat positive effect on most consumers, while 46% say it has a very or somewhat negative effect.","6a9098b7e81f0249cd72d6a6","2026-08-28T05:26:14.544Z",{"title":388,"description":389},"Gallup: 17% of Americans Smoke Cannabis","A new Gallup poll finds 17% of U.S. adults smoke cannabis and 15% consume edibles, with consumption highest among adults aged 30–49.",[391],{"name":103,"url":375,"trustTier":57,"_id":392},"6a9098b7e81f0249cd72d6a2","A new Gallup poll finds 17% of U.S. adults say they smoke cannabis, tying the record high from 2023, while 15% report consuming cannabis edibles. Consumption is highest among adults aged 30–49, and Americans remain closely divided on whether cannabis has a positive or negative effect on most users.","2026-08-28T05:26:14.654Z",{"_id":396,"slug":397,"articleType":8,"body":398,"createdAt":403,"dek":404,"entities":405,"headline":413,"imageAlt":414,"imageUrl":35,"keyFacts":415,"language":50,"publishedAt":386,"seo":429,"sources":432,"summary":435,"updatedAt":436},"6a9098ddaeddfad21a39f9da","medical-cannabis-access-linked-to-7-drop-in-health-related-work-absences-study-finds-f991f0e3",[399,400,401,402],"Health-related work absences dropped by roughly 7% in states with medical cannabis access, according to a University of Georgia study published in the Journal of Workplace and Behavioral Health. The research drew on responses from more than 20 million people in a U.S. Census Bureau and U.S. Bureau of Labor Statistics dataset spanning 1990 to 2025.","The effect was strongest in physically demanding occupations, including manual labor and machinery operation, and in industries such as construction and agriculture. Health service workers also showed significant declines in health-related absences.","Patryk Babiarz, the study's corresponding author and an associate professor in the UGA College of Family and Consumer Sciences, said work absenteeism costs employers heavily, with one estimate placing the total at $225 billion annually in lost productivity alone. He added that medical marijuana could save hundreds of millions of dollars in economic cost simply because people are not missing work.","Researchers suggested that access to medical cannabis could be reducing symptoms associated with chronic pain, alleviating the need to take sick leave, though the data could not directly confirm cannabis use for pain management. Adult-use cannabis laws did not influence health-related absenteeism, regardless of whether cannabis was legal for retail sale or simply decriminalized. The study did not examine potential adverse effects of cannabis use, such as negative health and behavioral outcomes.","2026-08-27T20:06:53.207Z","A University of Georgia analysis of more than 20 million survey responses finds fewer sick days in states with medical cannabis laws, with the strongest effect in physically demanding jobs.",{"brands":406,"products":407,"markets":408,"organizations":409},[],[],[21],[410,411,412],"University of Georgia","U.S. Census Bureau","U.S. Bureau of Labor Statistics","Medical Cannabis Access Linked to 7% Drop in Health-Related Work Absences, Study Finds","A worker in a physically demanding job, such as construction or agriculture, representing reduced health-related work absences in states with medical cannabis access.",[416,420,423,426],{"claim":417,"sourceUrl":418,"_id":419},"Health-related work absences dropped by about 7% in states with medical cannabis access.","https:\u002F\u002Fganjapreneur.com\u002Fstudy-health-related-work-absences-drop-7-in-states-with-medical-cannabis-access\u002F","6a9098dde81f0249cd72d6e5",{"claim":421,"sourceUrl":418,"_id":422},"The study analyzed responses from more than 20 million people in a U.S. Census Bureau and U.S. Bureau of Labor Statistics dataset between 1990 and 2025.","6a9098dde81f0249cd72d6e6",{"claim":424,"sourceUrl":418,"_id":425},"The effect was strongest in physically demanding occupations, such as manual labor and machinery operation, and in industries like construction and agriculture.","6a9098dde81f0249cd72d6e7",{"claim":427,"sourceUrl":418,"_id":428},"Adult-use cannabis laws did not influence health-related absenteeism, regardless of whether cannabis was legal for retail sale or simply decriminalized.","6a9098dde81f0249cd72d6e8",{"title":430,"description":431},"Medical Cannabis Access Tied to 7% Drop in Work Absences","A University of Georgia study finds health-related work absences fell about 7% in states with medical cannabis access, with the strongest effect in physical jobs.",[433],{"name":103,"url":418,"trustTier":57,"_id":434},"6a9098dde81f0249cd72d6e4","Health-related work absences fell by about 7% in states with medical cannabis access, according to a University of Georgia study published in the Journal of Workplace and Behavioral Health. Researchers analyzed U.S. Census Bureau and Bureau of Labor Statistics data from 1990 to 2025, finding the largest reductions in manual labor, machinery operation, construction, agriculture, and health services. Adult-use laws showed no effect on absenteeism.","2026-08-28T05:26:14.658Z",{"page":438,"limit":439,"total":440,"pages":438},1,18,9,{"data":442},{"types":443,"markets":469,"brands":623,"latestPublishedAt":751},[444,447,450,451,453,456,459,461,464,466],{"value":445,"count":446},"regulation",35,{"value":448,"count":449},"market",25,{"value":8,"count":440},{"value":452,"count":440},"m_and_a",{"value":454,"count":455},"enforcement",6,{"value":457,"count":458},"finance",4,{"value":460,"count":458},"licensing",{"value":462,"count":463},"brand_launch",3,{"value":465,"count":463},"other",{"value":467,"count":468},"product_launch",2,[470,472,475,478,480,482,484,486,487,489,491,493,495,497,499,501,503,505,506,508,510,512,514,516,518,520,522,524,526,528,530,532,534,536,538,540,542,544,546,548,550,552,554,556,558,559,561,563,565,567,569,570,572,574,576,577,579,581,583,585,587,589,590,592,594,596,597,598,600,602,604,606,608,610,612,614,616,618,620,622],{"value":26,"count":471},19,{"value":473,"count":474},"Canada",15,{"value":476,"count":477},"Germany",11,{"value":479,"count":477},"California",{"value":481,"count":440},"UK",{"value":483,"count":455},"Illinois",{"value":485,"count":455},"Colorado",{"value":367,"count":455},{"value":488,"count":455},"Michigan",{"value":490,"count":458},"Spain",{"value":492,"count":458},"New York",{"value":494,"count":458},"Australia",{"value":496,"count":463},"Texas",{"value":498,"count":463},"France",{"value":500,"count":463},"South Africa",{"value":502,"count":463},"Portugal",{"value":504,"count":463},"Massachusetts",{"value":77,"count":463},{"value":507,"count":463},"Montana",{"value":509,"count":463},"Poland",{"value":511,"count":468},"Nebraska",{"value":513,"count":468},"Rhode Island",{"value":515,"count":468},"Alabama",{"value":517,"count":468},"North Carolina",{"value":519,"count":468},"Washington State",{"value":521,"count":468},"Pennsylvania",{"value":523,"count":468},"US federal",{"value":525,"count":468},"Arizona",{"value":527,"count":468},"Thailand",{"value":529,"count":468},"Ohio",{"value":531,"count":468},"Minnesota",{"value":533,"count":468},"Kentucky",{"value":535,"count":468},"Delaware",{"value":537,"count":468},"Europe",{"value":539,"count":468},"Virginia",{"value":541,"count":468},"Maryland",{"value":543,"count":468},"Maine",{"value":545,"count":438},"North Macedonia",{"value":547,"count":438},"TSX",{"value":549,"count":438},"North America",{"value":551,"count":438},"hemp market",{"value":553,"count":438},"New Hampshire",{"value":555,"count":438},"Oklahoma",{"value":557,"count":438},"BC",{"value":25,"count":438},{"value":560,"count":438},"retail cannabis",{"value":562,"count":438},"Humboldt County, California",{"value":564,"count":438},"NASDAQ",{"value":566,"count":438},"District of Columbia",{"value":568,"count":438},"New Jersey",{"value":21,"count":438},{"value":571,"count":438},"EU",{"value":573,"count":438},"New Mexico",{"value":575,"count":438},"Oregon",{"value":167,"count":438},{"value":578,"count":438},"Sacramento, California",{"value":580,"count":438},"Latin America",{"value":582,"count":438},"Utah",{"value":584,"count":438},"Florida",{"value":586,"count":438},"CA",{"value":588,"count":438},"Washington, D.C.",{"value":172,"count":438},{"value":591,"count":438},"Global",{"value":593,"count":438},"Georgia",{"value":595,"count":438},"Connecticut",{"value":319,"count":438},{"value":321,"count":438},{"value":599,"count":438},"Wyoming",{"value":601,"count":438},"hemp",{"value":603,"count":438},"Ireland",{"value":605,"count":438},"cannabis",{"value":607,"count":438},"Mississippi",{"value":609,"count":438},"Indiana",{"value":611,"count":438},"Wisconsin",{"value":613,"count":438},"Houston",{"value":615,"count":438},"OTCQX",{"value":617,"count":438},"San Francisco",{"value":619,"count":438},"Missouri",{"value":621,"count":438},"Turkey",{"value":320,"count":438},[624,626,628,630,632,634,636,638,640,641,643,645,647,649,651,653,655,657,659,661,663,665,667,669,671,673,675,677,679,681,683,685,687,689,691,693,695,697,699,701,703,705,707,709,711,713,715,717,719,721,723,725,727,729,731,733,735,737,739,741,743,745,747,749],{"value":625,"count":455},"Aurora Cannabis",{"value":627,"count":458},"Curaleaf",{"value":629,"count":468},"Curaleaf Holdings",{"value":631,"count":468},"Target",{"value":633,"count":468},"Safari Flower Company",{"value":635,"count":438},"BevMo! by Gopuff",{"value":637,"count":438},"Gramz",{"value":639,"count":438},"Green Thumb Industries",{"value":219,"count":438},{"value":642,"count":438},"AYR Wellness Inc.",{"value":644,"count":438},"R'belle",{"value":646,"count":438},"Square",{"value":648,"count":438},"Sonoran Roots",{"value":650,"count":438},"Dunbar Pharma",{"value":652,"count":438},"Verano Holdings LLC",{"value":654,"count":438},"Rx Green Technologies",{"value":656,"count":438},"Total Wine & More",{"value":658,"count":438},"High Rollers",{"value":660,"count":438},"High Tide",{"value":662,"count":438},"Sunnyside",{"value":664,"count":438},"Beast Media",{"value":666,"count":438},"The Woods",{"value":668,"count":438},"HiWay",{"value":670,"count":438},"Decibel Cannabis",{"value":672,"count":438},"Trulieve",{"value":674,"count":438},"Cannabis Health",{"value":676,"count":438},"ABC Fine Wine & Spirits",{"value":678,"count":438},"Prohibition Partners",{"value":680,"count":438},"Cresco",{"value":682,"count":438},"Business of Cannabis",{"value":684,"count":438},"Callie's Apothecary",{"value":686,"count":438},"IPS Pharma",{"value":688,"count":438},"Ascend Wellness Holdings Inc.",{"value":690,"count":438},"Curaleaf Inc.",{"value":692,"count":438},"Lovewell Farms",{"value":694,"count":438},"Cannabis Europa",{"value":696,"count":438},"Exilby",{"value":698,"count":438},"Remexian",{"value":700,"count":438},"Vertanical",{"value":702,"count":438},"Spec's Wine and Spirits & Finer Foods",{"value":704,"count":438},"Higher Love Cannabis Co.",{"value":706,"count":438},"Aery Group",{"value":708,"count":438},"Cova Software",{"value":710,"count":438},"Jetty",{"value":712,"count":438},"Blue Sage",{"value":714,"count":438},"JARS Cannabis",{"value":716,"count":438},"Claybourne",{"value":718,"count":438},"Pedanios",{"value":720,"count":438},"Lotus Farmacy",{"value":722,"count":438},"Epidiolex",{"value":724,"count":438},"EmpowHer Cannabis Society",{"value":726,"count":438},"Trulieve Inc.",{"value":728,"count":438},"Terps USA",{"value":730,"count":438},"Ponderosa Dispensary",{"value":732,"count":438},"iAnthus",{"value":734,"count":438},"Mind Forward",{"value":736,"count":438},"Tweed",{"value":738,"count":438},"WaterClear THC",{"value":740,"count":438},"Blunt Brunch",{"value":742,"count":438},"Sativex",{"value":744,"count":438},"PPX",{"value":746,"count":438},"Storz & Bickel",{"value":748,"count":438},"Team Winston",{"value":750,"count":438},"BamaBloom","2026-09-17T18:05:05.641Z"]